Zurich-based biotechnology company Inositec has appointed a new chief medical officer in the form of Dr Frits van Alphen.
He said: “As CMO of Inositec, I have the golden opportunity to utilise my broad experience and entrepreneurial mind-set to develop new medicines.
“These innovative products have the potential to significantly advance patient care in vascular and other calcification disorders, all with high unmet medical need.”
Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at Novartis as well as heading their clinical operations team in the Netherlands.
Dr Mattias Ivarsson, chief medical officer of Inositec, said: “Dr van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with out lead programme in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019.”